Literature DB >> 17023019

Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.

Nicole Brimer1, Charles Lyons, Scott B Vande Pol.   

Abstract

The cellular E3 ubiquitin ligase E6AP (UBE3A) interacts with the cancer-associated HPV E6 oncoproteins, where together with the viral E6 oncoprotein it binds and targets the degradation of the p53 tumor suppressor. We find that the HPV-11E6 protein also associates with E6AP in vivo, and thereby can target the degradation of an E6-associated protein. Mutation of an E6-binding LXXLL peptide motif on E6AP eliminated the association, revealing a common mode of interaction between high- and low-risk E6 proteins and E6AP. E6AP was required for the in vivo degradation of DLG1 by both HVP-18 E6 and a chimeric HPV-11E6. The common functional interaction of both cancer-associated and non-cancer-associated E6 proteins with E6AP establishes a common mechanism for E6 proteins trophic to mucosal squamous epithelium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023019      PMCID: PMC1892534          DOI: 10.1016/j.virol.2006.08.038

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

Review 1.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.

Authors:  Brooke Cooper; Steven Schneider; Joanna Bohl; Yong hui Jiang; Arthur Beaudet; Scott Vande Pol
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

3.  Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein.

Authors:  J Bohl; K Das; B Dasgupta; S B Vande Pol
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

4.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

5.  Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.

Authors:  W H Kao; S L Beaudenon; A L Talis; J M Huibregtse; P M Howley
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system.

Authors:  O Elroy-Stein; T R Fuerst; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent.

Authors:  Helena Sterlinko Grm; Lawrence Banks
Journal:  J Gen Virol       Date:  2004-10       Impact factor: 3.891

8.  Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins.

Authors:  David Pim; Miranda Thomas; Lawrence Banks
Journal:  Oncogene       Date:  2002-11-21       Impact factor: 9.867

9.  Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11.

Authors:  Stephen T Oh; Michelle S Longworth; Laimonis A Laimins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides.

Authors:  Helena Sterlinko Grm; Malte Weber; Rob Elston; Pauline McIntosh; Heather Griffin; Lawrence Banks; John Doorbar
Journal:  J Mol Biol       Date:  2004-01-23       Impact factor: 5.469

View more
  39 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 2.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

3.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Transformation by bovine papillomavirus type 1 E6 requires paxillin.

Authors:  Ramon Wade; Nicole Brimer; Scott Vande Pol
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance.

Authors:  Shiyuan Hong; Kavi P Mehta; Laimonis A Laimins
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

Review 6.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

7.  Human Papillomavirus 11 Early Protein E6 Activates Autophagy by Repressing AKT/mTOR and Erk/mTOR.

Authors:  Boya Zhang; Yinjing Song; Siyuan Sun; Rui Han; Chunting Hua; Stijn van der Veen; Hao Cheng
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

Review 8.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

9.  Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.

Authors:  Nicole Brimer; Scott B Vande Pol
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

10.  PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6.

Authors:  Carina H Storrs; Saul J Silverstein
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.